New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
Among 'a lot of brilliant guys,' the leukemia clinician-researcher stood out for his science — and much more
June 2, 2017
| By Mary Engel / Fred Hutch News Service
Dr. Steven J. Collins' research into the molecular genetics of myeloid leukemias changed the way scientists thought about cancer cells and led to the development of one of the earliest targeted therapies.
Dr. Glenda Gray among Time magazine’s ‘100 most influential’; Fred Hutch license plates coming soon; UW establishes Dr. Oliver W. Press Distinguished MSTP Alumnus Award; and Dr. Vivian Oehler receives ASH Bridge Grant for leukemia research.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.